Every Form 4 that Apellis Pharmace (APLS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow APLS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APLS filings page.
Apellis Pharmaceuticals VP and Chief Accounting Officer James George Chopas reported a sale of 873 shares of Apellis common stock on January 13, 2026 at a price of $22.1872 per share. According to the filing, this sale was made to cover tax withholding on restricted stock units that were released on January 12, 2026, meaning it was tied to an equity compensation event rather than an open-market discretionary sale. Following this transaction, Chopas beneficially owned 52,595 shares of Apellis common stock in direct ownership.
Apellis Pharmaceuticals, Inc. (APLS) reported an insider tax-related share sale by its Chief Business & Strat Officer, Mark DeLong. On January 13, 2026, DeLong sold 1,780 shares of Apellis common stock at a price of $22.1872 per share. According to the footnotes, these shares were sold solely to cover tax withholding on Restricted Stock Units that were released on January 12, 2026. Following this transaction, DeLong beneficially owned 83,058 shares of Apellis common stock, which includes 893 shares acquired through the company’s employee stock purchase plan on April 30, 2025.
Apellis Pharmaceuticals' Chief Scientific Officer, Pascal Deschatelets, reported a small insider stock sale. On January 13, 2026, he sold 2,277 shares of Apellis common stock at a price of $22.1872 per share. According to the footnote, these shares were sold solely to cover tax withholding on Restricted Stock Units that were released on January 12, 2026.
After this transaction, Deschatelets beneficially owned 1,158,219 shares of Apellis common stock in direct form. The filing is made as a Form 4 by a single reporting person in his capacity as Chief Scientific Officer.
Apellis Pharmaceuticals CEO Cedric Francois, who also serves as a director, reported a sale of common stock. On January 13, 2026, he sold 10,186 shares of Apellis common stock at a price of $22.1872 per share, leaving him with 321,419 shares held directly. The filing explains that this sale was made to cover tax withholding on restricted stock units that were released on January 12, 2026.
In addition to his direct holdings, the filing lists indirect holdings in several trusts: 307,946 shares held by The Cedric Francois Irrevocable Trust of 2023 - 2, 472,065 shares held by The Cedric Francois Irrevocable Trust of 2023, 300,000 shares held by The Francois Grossi Trust, and 234,411 shares held by The Francois-DuBois Educational Trust. For each of these trusts, the filing states that Francois disclaims beneficial ownership of the shares except to the extent of his pecuniary interest.
Apellis Pharmaceuticals' Chief Technical Officer Nur Nicholson reported a sale of company stock. On January 13, 2026, Nicholson sold 2,618 shares of Apellis common stock at a price of $22.1872 per share. According to the disclosure, these shares were sold to cover tax withholding on Restricted Stock Units that were released on January 12, 2026, meaning the transaction was tied to an equity award rather than an open-market discretionary sale of the full grant.
After this tax-related sale, Nicholson beneficially owned 81,046 shares of Apellis common stock in direct ownership. The filing is made as a Form 4, which reports changes in insider ownership for officers, and confirms Nicholson’s role as Chief Technical Officer of Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals Chief Financial Officer Timothy Sullivan reported a sale of company common stock. On January 13, 2026, he sold 3,856 shares at a price of $22.1872 per share, a transaction code "S". According to the footnotes, these shares were sold solely to cover tax withholding related to restricted stock units that were released on January 12, 2026, rather than as a discretionary open-market sale.
After this transaction, Sullivan directly held 107,080 shares of Apellis common stock. In addition, 60,396 shares are held indirectly by The Timothy E Sullivan Irrevocable Trust of 2023. A separate footnote explains that Patrick O. Collins is the trustee of this trust and that Sullivan disclaims beneficial ownership of those trust-held shares except to the extent of his pecuniary interest in them.
Apellis Pharmaceuticals General Counsel David O. Watson reported a small open-market sale of company stock. On January 13, 2026, he sold 5,780 shares of common stock at a price of $22.1872 per share under transaction code "S". The footnotes explain this sale was made to cover tax withholding on restricted stock units that were released on January 12, 2026.
After the sale, Watson beneficially owned 98,838 Apellis common shares directly. He also had indirect holdings of 10,000 shares in a custodial account for his minor children and 50,136 shares held by The David O. Watson Irrevocable Trust of 2023, where he disclaims beneficial ownership except for any pecuniary interest.
Apellis Pharmaceuticals general counsel David O. Watson reported an insider equity transaction. On January 7, 2026, he exercised a stock option for 888 shares of Apellis common stock at an exercise price of $14.95 per share. Following this option exercise, he directly holds 104,618 shares of Apellis common stock.
The filing also lists indirect holdings. A custodial account for his minor children holds 10,000 shares. In addition, 50,136 shares are held by The David O. Watson Irrevocable Trust of 2023, for which William Zorn serves as trustee; Watson disclaims beneficial ownership of those trust shares except to the extent of his pecuniary interest.
Apellis Pharmaceuticals Chief Medical Officer Caroline Baumal reported a sale of common stock. On January 5, 2026, she sold 3,020 shares of Apellis Pharmaceuticals, Inc. common stock at a price of $25.5287 per share. According to the disclosure, these shares were sold to cover tax withholding obligations arising from Restricted Stock Units that were released on January 3, 2026, rather than as a discretionary open-market sale. Following this transaction, Baumal beneficially owns 91,206 shares of common stock directly, which includes 925 shares acquired through an employee stock purchase plan on October 31, 2025.
Apellis Pharmaceuticals officer David Watson reported a planned sale of 5,000 shares of Apellis common stock at $24.49 per share on December 16, 2025, coded as an "S" transaction. The filing notes this was a scheduled sale under a Rule 10b5-1 trading plan dated March 3, 2025.
After the sale, Watson directly owned 103,730 shares. He also had indirect ownership of 10,000 shares held in a custodial account for the sole benefit of his minor children and 50,136 shares held by The David O. Watson Irrevocable Trust of 2023, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
Apellis Pharmaceuticals, Inc. (APLS) reported an insider transaction by its General Counsel, David Watson. On 11/17/2025, he sold 5,000 shares of common stock at a price of $20.06 per share in a transaction coded as a sale. The filing states this was a scheduled sale under a Rule 10b5-1 trading plan dated March 3, 2025.
After this transaction, David Watson beneficially owns 108,730 shares of Apellis common stock directly. He also reports indirect ownership of 10,000 shares through a custodial account for his minor children and 50,136 shares held by The David O. Watson Irrevocable Trust of 2023, over which he disclaims beneficial ownership except to the extent of his pecuniary interest.
Apellis Pharmaceuticals (APLS) reported an insider transaction by CFO Timothy Sullivan. On October 21, 2025, he exercised stock options for 10,000 shares at $10.03 and sold 10,000 shares at $28.03 under a Rule 10b5-1 trading plan.
After these transactions, he held 110,936 shares directly and 60,396 shares indirectly through The Timothy E Sullivan Irrevocable Trust of 2023. He also reported 232,903 derivative securities (stock options) beneficially owned following the transactions.
Apellis Pharmaceuticals (APLS) General Counsel David Watson reported a sale of 5,000 shares of common stock at $25.22 on 10/16/2025 pursuant to a Rule 10b5-1 trading plan dated March 3, 2025.
After the transaction, he beneficially owned 113,730 shares directly, plus 10,000 shares held indirectly via a custodial account for his minor children and 50,136 shares held by The David O. Watson Irrevocable Trust of 2023.
Apellis Pharmaceuticals (APLS): Director insider activity reported on Form 4. On 06/24/2025, the reporting person transferred 4,787 shares for no consideration to Epidarex. On 10/10/2025, Epidarex sold 31,092 shares at a weighted average price of $23.7211 under a Rule 10b5-1 trading plan adopted on June 20, 2025. Following the sale, 3,837 shares were held indirectly via Epidarex, then distributed for no consideration, resulting in 0 shares held indirectly. Direct ownership after the 06/24 transfer was 153,606 shares.
Apellis Pharmaceuticals director Dunlop A. Sinclair reported multiple dispositions of Apellis common stock on 09/30/2025. The filing shows a sale of 31,092 shares at a weighted average price of $22.58 (individual sale prices ranged from $22.23 to $22.74). The filer states these sales were executed under a Rule 10b5-1 trading plan adopted by Epidarex Capital I LP on June 20, 2025. The report lists an additional 3,837-share distribution at no consideration and includes a separate disposition line showing 158,393 shares disposed, without price detail in the table. Sinclair is identified as a director and as having indirect ownership through Epidarex, which holds voting and dispositive power over the shares.
Dunlop A. Sinclair, a director of Apellis Pharmaceuticals (APLS), reported multiple dispositions of Apellis common stock on 09/19/2025. Sales include 31,092 shares sold under a Rule 10b5-1 plan at a weighted-average price of $22.95 (execution prices ranged $22.73–$23.27). A separate distribution of 3,837 shares was recorded as a stock distribution for no consideration. The reported holdings after the first two transactions were 68,908 and 65,071 shares, respectively, held indirectly through Epidarex Capital I LP, of which Sinclair is a general partner and may be deemed to have voting and dispositive power. The Form 4 was signed by an attorney-in-fact on behalf of Sinclair.
David O. Watson, General Counsel of Apellis Pharmaceuticals (APLS), reported a sale of 5,000 shares of Apellis common stock on 09/16/2025 at a price of $24.34 per share under a 10b5-1 trading plan dated March 3, 2025. After the reported transaction, Mr. Watson beneficially owns 118,730 shares directly. The filing also discloses 10,000 shares held in a custodial account for his minor children and 50,136 shares held by The David O. Watson Irrevocable Trust of 2023, over which he disclaims beneficial ownership except to the extent of any pecuniary interest. The Form 4 was signed on 09/18/2025.
Apellis Pharmaceuticals insider James G. Chopas, the company's VP and Chief Accounting Officer, reported a small sale of 189 shares of Apellis common stock on 09/15/2025 at a price of $24.192 per share. The filing states the shares were sold to cover tax withholding related to Restricted Stock Units that vested on 09/12/2025. After the transaction, Mr. Chopas beneficially owned 53,468 shares, held directly. The Form 4 was signed by an attorney-in-fact on 09/16/2025.